Skip to main content
Premium Trial:

Request an Annual Quote

Payment from Gen-Probe Drives Sharp Q2 Revenue Increase for DiagnoCure

NEW YORK (GenomeWeb News) – Cancer diagnostics company DiagnoCure's fiscal second-quarter revenues more than tripled, it reported after the close of the market on Wednesday, driven in part by a milestone payment from Gen-Probe.

For the three months ended April 30, Quebec City-based DiagnoCure recorded C$1.1 million (US$1.1 million) in revenues, up from C$310,907 in the year-ago period.

The recent quarter includes a milestone payment from Gen-Probe of C$502,600 subsequent to the US Food and Drug Administration's approval of Gen-Probe's Progensa PCA3 assay, the first molecular test for prostate cancer to aid physicians in evaluating the need for repeat prostate biopsies in men who have had a previous negative biopsy. Gen-Probe acquired the exclusive worldwide diagnostic rights to the PCA3 gene from DiagnoCure in late 2003.

In the year-ago period, DiagnoCure received C$123,801 as part of an annual payment from Gen-Probe based on an amended agreement between the two firms reached in 2009.

In Q2 2012, total royalty payments to DiagnoCure slid 7 percent year over year to C$173,264 from C$187,106. Royalty payments from Gen-Probe increased to C$168,663 from C$163,840, but royalty payments from Scimedx related to bladder cancer tests distributed under the names ImmunoCyt and uCyt+ fell to C$4,601 from C$23,266, DiagnoCure said.

The company also received C$387,267 in R&D services from Signal Genetics associated with the Previstage GCC Colorectal Cancer Staging Test.

DiagnoCure's R&D expenses during Q2 2012 slid to C$694,950 from C$721,350 a year ago, while SG&A costs decreased to C$562,700 from C$621,063.

The firm's net loss from continuing operations for the quarter came in at C$270,147, or C$.01 per share, compared to a net loss of C$1.1 million, or C$.02 per share a year ago.

DiagnoCure ended the quarter with C$7.4 million in cash, cash equivalents, temporary, and long-term investments, it said.

The Scan

Wolf Howl Responses Offer Look at Vocal Behavior-Related Selection in Dogs

In dozens of domestic dogs listening to wolf vocalizations, researchers in Communication Biology see responses varying with age, sex, reproductive status, and a breed's evolutionary distance from wolves.

Facial Imaging-Based Genetic Diagnoses Appears to Get Boost With Three-Dimensional Approach

With data for more than 1,900 individuals affected by a range of genetic conditions, researchers compared facial phenotype-based diagnoses informed by 2D or 3D images in the European Journal of Human Genetics.

Survey Suggests Multigene Cancer Panel VUS Reporting May Vary Across Genetic Counselors

Investigators surveyed dozens of genetic counselors working in clinical or laboratory settings, uncovering attitudes around VUS reporting after multigene cancer panel testing in the Journal of Genetic Counseling.

Study Points to Tuberculosis Protection by Gaucher Disease Mutation

A mutation linked to Gaucher disease in the Ashkenazi Jewish population appears to boost Mycobacterium tuberculosis resistance in a zebrafish model of the lysosomal storage condition, a new PNAS study finds.